1. Scrip
  2. >>Business

CEO Hudson: No Rust On Sanofi Launch Engine

 
• By Kevin Grogan

Some analysts have expressed concern in the past about the French drugmaker’s product launchpad but CEO Paul Hudson has dismissed such claims, pointing to the spectacular lift off of Beyfortus.

Sanofi
• Source: Sanofi

Having spent the past three months touting Sanofi's credentials as the pharma industry's leader in immunology R&D, CEO Paul Hudson has turned the spotlight on the French major's ability to launch products successfully, a position backed up by the stellar performance of the AstraZeneca PLC-partnered infant respiratory syncytial virus vaccine Beyfortus.

Presenting Sanofi's financials at its annual press conference in Paris, Hudson noted that the firm's key launches in 2023 –...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 
• By Jessica Merrill

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

Roche Keen To Cut Out The Middle Men On US Pricing

 
• By Kevin Grogan

The Swiss giant has been talking to the US government about selling medicines directly to patients.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By Kevin Grogan

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.